The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

ADHD is associated with impulsivity, hyperactivity, and trouble with focus, but kids with ADHD may also struggle with motor ...

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

ADHD can interfere with your quality of life and disrupt your work schedule. We know how busy life can get, and sometimes, it may feel impossible to make the time to see an in-person care provider.

Women are driving soaring use of ADHD medication, experts say. Researchers from the University of Oxford highlighted a ...

ADHD medication presciptions have surged in the UK over the past decade. Women have driven the record numbers, research ...

Prescriptions of ADHD medicines has tripled in the UK over the past decade with a particular stark increase in women aged ...

The use of medication to treat Attention-Deficit Hyperactivity Disorder (ADHD) has risen sharply in the UK, largely due to ...

There is no link between acetaminophen use in pregnancy and autism or ADHD risk for the offspring, a new gold-standard review ...

ADHD Advisor is a telehealth service connecting patients facing attention-deficit/hyperactivity disorder (ADHD) and other mental health challenges with licensed ...